BELLUS Health Inc. BLU
Set alert
14.75 0.00 0.00%
As of Jun 28, 3:59 PM ET
14.74 Day range 14.75
52-week range unavailable
- Open
- 14.74
- Prev close
- 14.75
- Mkt cap
- 1.87B
- Vol
- 2.84M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 14.74
- High
- 14.75
- Forward P/E
- -12.39
- Beta
- -0.28
- Short ratio
- 2.61
- Inst. own
- 90.41%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 9, 2023
- 50-d avg
- 14.59
- 200-d avg
- 10.22
- 1y target
- 16.05
2Y chart
Events in this range
- May 11, 2022Earnings: —; estimate -0.18; surprise —%
- Aug 10, 2022Earnings: —; estimate -0.17; surprise —%
- Nov 14, 2022Earnings: —; estimate -0.18; surprise —%
- Mar 21, 2023Earnings: —; estimate 0; surprise —%
- Mar 22, 2023Rating: HC Wainwright & Co. · — → Buy
- Mar 22, 2023Rating: RBC Capital · — → Outperform
- Apr 18, 2023Downgrade: Evercore ISI Group · Outperform → In-Line
- Apr 19, 2023Downgrade: Jefferies · Buy → Hold
- Apr 19, 2023Downgrade: RBC Capital · Outperform → Sector Perform
- May 12, 2023Earnings: —; estimate -0.2; surprise —%
- May 15, 2023Rating: RBC Capital · Sector Perform → Sector Perform
Signals (64)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | May 8, 2023 | 3 years ago |
| SMA: Bullish | Apr 18, 2023 | 3 years ago |
| SMA: Bullish | Apr 18, 2023 | 3 years ago |
| RSI: Overbought | Apr 18, 2023 | 3 years ago |
| MACD: Buy Signal | Apr 13, 2023 | 3 years ago |
| RSI: Oversold | Apr 5, 2023 | 3 years ago |
| MACD: Sell Signal | Mar 27, 2023 | 3 years ago |
| MACD: Buy Signal | Mar 3, 2023 | 3 years ago |
| MACD: Sell Signal | Mar 2, 2023 | 3 years ago |
| MACD: Buy Signal | Mar 1, 2023 | 3 years ago |
| MACD: Sell Signal | Feb 21, 2023 | 3 years ago |
| MACD: Buy Signal | Jan 20, 2023 | 3 years ago |
| RSI: Oversold | Jan 9, 2023 | 3 years ago |
| SMA: Bearish | Dec 19, 2022 | 3 years ago |
| SMA: Bearish | Dec 19, 2022 | 3 years ago |
| MACD: Sell Signal | Dec 16, 2022 | 3 years ago |
| SMA: Bullish | Nov 30, 2022 | 3 years ago |
| SMA: Bullish | Nov 10, 2022 | 3 years ago |
| MACD: Buy Signal | Nov 10, 2022 | 3 years ago |
| SMA: Bearish | Nov 9, 2022 | 3 years ago |
| SMA: Bullish | Nov 8, 2022 | 3 years ago |
| SMA: Bearish | Nov 7, 2022 | 3 years ago |
| MACD: Sell Signal | Nov 4, 2022 | 3 years ago |
| MACD: Buy Signal | Oct 25, 2022 | 4 years ago |
| SMA: Bearish | Sep 21, 2022 | 4 years ago |
| SMA: Bullish | Sep 19, 2022 | 4 years ago |
| SMA: Bearish | Sep 16, 2022 | 4 years ago |
| MACD: Sell Signal | Aug 19, 2022 | 4 years ago |
| RSI: Overbought | Aug 5, 2022 | 4 years ago |
| MACD: Buy Signal | Aug 3, 2022 | 4 years ago |
| MACD: Sell Signal | Jul 14, 2022 | 4 years ago |
| RSI: Overbought | Jul 6, 2022 | 4 years ago |
| RSI: Overbought | Jun 29, 2022 | 4 years ago |
| SMA: Bullish | Jun 24, 2022 | 4 years ago |
| MACD: Buy Signal | Jun 24, 2022 | 4 years ago |
| SMA: Bearish | Jun 13, 2022 | 4 years ago |
| MACD: Sell Signal | Jun 13, 2022 | 4 years ago |
| MACD: Buy Signal | Jun 6, 2022 | 4 years ago |
| SMA: Bullish | Jun 2, 2022 | 4 years ago |
| SMA: Bearish | Jun 1, 2022 | 4 years ago |
| SMA: Bullish | May 27, 2022 | 4 years ago |
| SMA: Bearish | May 26, 2022 | 4 years ago |
| MACD: Sell Signal | May 24, 2022 | 4 years ago |
| MACD: Buy Signal | May 17, 2022 | 4 years ago |
| SMA: Bullish | May 12, 2022 | 4 years ago |
| SMA: Bearish | May 9, 2022 | 4 years ago |
| MACD: Sell Signal | Apr 27, 2022 | 4 years ago |
| RSI: Overbought | Apr 19, 2022 | 4 years ago |
| RSI: Overbought | Apr 12, 2022 | 4 years ago |
| RSI: Overbought | Apr 6, 2022 | 4 years ago |
| SMA: Bullish | Mar 29, 2022 | 4 years ago |
| SMA: Bearish | Mar 25, 2022 | 4 years ago |
| SMA: Bullish | Mar 24, 2022 | 4 years ago |
| SMA: Bearish | Mar 23, 2022 | 4 years ago |
| SMA: Bullish | Mar 17, 2022 | 4 years ago |
| MACD: Buy Signal | Mar 17, 2022 | 4 years ago |
| MACD: Sell Signal | Feb 23, 2022 | 4 years ago |
| SMA: Bearish | Feb 22, 2022 | 4 years ago |
| SMA: Bullish | Feb 7, 2022 | 4 years ago |
| SMA: Bearish | Feb 4, 2022 | 4 years ago |
| SMA: Bullish | Feb 2, 2022 | 4 years ago |
| MACD: Buy Signal | Feb 1, 2022 | 4 years ago |
| MACD: Sell Signal | Jan 5, 2022 | 4 years ago |
| RSI: Oversold | Dec 2, 2021 | 4 years ago |
Key statistics
- Market cap
- 1.87B
- Enterprise value
- 1.56B
- Trailing P/E
- 0.00
- Forward P/E
- -12.39
- PEG ratio
- 0.00
- Price / sales
- 124613.92
- Price / book
- 5.06
- EPS (TTM)
- -0.73
- Beta
- -0.28
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 15.00K
- Revenue growth
- -25.00%
- Free cash flow
- -54.76M
- Total cash
- 312.99M
- Total debt
- 1.20M
- Return on equity
- -26.76%
- Shares outstanding
- 126.81M
- Short % of float
- 0.00%
- 50-day average
- 14.59
- 200-day average
- 10.22
Analyst view
Consensus: buy
Buy
Price target (mean) 16.05 +8.9% upside
Now 14.75
- Target (low)
- 14.75
- Target (mean)
- 16.05
- Target (high)
- 20.00
Next earnings
Aug 9, 2023
Expected Aug 9, 2023. Consensus EPS estimate -0.24.
Financials — quick view
BLU Revenue — quarterly 0
BLU Net income — quarterly -25.06M
BLU EPS — quarterly -0.20
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 9, 2023 | Jun 1, 2023 | -0.24 | — | — | — |
| May 12, 2023 | Mar 1, 2023 | -0.20 | — | — | — |
| Mar 21, 2023 | Dec 1, 2022 | 0.00 | — | — | — |
| Nov 14, 2022 | Sep 1, 2022 | -0.18 | — | — | — |
| Aug 10, 2022 | Jun 1, 2022 | -0.17 | — | — | — |
| May 11, 2022 | Mar 1, 2022 | -0.18 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 15, 2023 | RBC Capital | reit | Sector Perform | Sector Perform |
| Apr 19, 2023 | RBC Capital | down | Outperform | Sector Perform |
| Apr 19, 2023 | Jefferies | down | Buy | Hold |
| Apr 18, 2023 | Evercore ISI Group | down | Outperform | In-Line |
| Mar 22, 2023 | RBC Capital | reit | — | Outperform |
| Mar 22, 2023 | HC Wainwright & Co. | reit | — | Buy |
About BELLUS Health Inc.
BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada. As of June 28, 2023, BELLUS Health Inc. operates as a subsidiary of GSK plc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- bellushealth.com
News
- BLUENERGIES ANNOUNCES CLOSING OF NON-BROKERED PRIVATE PLACEMENT OF UNITS FOR GROSS PROCEEDS OF C$20.7 MILLION
- Bellus Health shareholders say yes to US$2B GSK takeover
- BELLUS Health Inc. Announces Voting Results from Special Meeting of Shareholders
- Alliance Entertainment Reports Third Quarter and Nine Month Fiscal 2023 Financial Results
- BELLUS Santé inc. convoque une assemblée extraordinaire des actionnaires concernant l’acquisition de la société par GSK
- BELLUS Health Inc. Calls Special Shareholders' Meeting in Connection with GSK Acquisition
- BELLUS Santé annonce ses résultats financiers et faits saillants pour le premier trimestre de 2023
- BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights
- BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights
- Tommy Hilfiger, Mercedes-AMG PETRONAS Formula One Team e Awake NY lanciano una collaborazione al Grand Prix di Miami
Your note
Sign in to keep a note on BLU — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| Bellini (Francesco) | Director of Issuer | Exercise of options | Nov 24, 2022 | 345,077 |
| Bellini (Roberto) | Director of Issuer | Exercise of options | Nov 24, 2022 | 1,010,403 |
| Desjardins, Francois | Senior Officer of Issuer | Acquisition or disposition in the public market | Mar 31, 2022 | 8,333 |
| Garceau, Denis | Senior Officer of Issuer | Acquisition or disposition in the public market | Mar 2, 2022 | 34,934 |
| Matzouranis (Tony) | Senior Officer of Issuer | Acquisition or disposition in the public market | Mar 2, 2022 | 24,391 |
| Naud (Nathalie) | Senior Officer of Issuer | Acquisition or disposition in the public market | Mar 8, 2022 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RA Capital Management, L.P. | 9.97% | 12,643,574 | 186.37M | Mar 30, 2023 |
| Goldman Sachs Group Inc | 5.85% | 7,413,933 | 109.28M | Mar 30, 2023 |
| Pictet Asset Management SA | 5.58% | 7,072,143 | 104.24M | Mar 30, 2023 |
| Commodore Capital Lp | 5.19% | 6,579,359 | 96.98M | Mar 30, 2023 |
| Orbimed Advisors LLC. | 4.03% | 5,108,900 | 75.31M | Mar 30, 2023 |
| Perceptive Advisors Llc | 3.91% | 4,952,538 | 73.00M | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Select Portfolios - Biotechnology | 1.28% | 1,621,196 | 23.90M | Feb 27, 2023 |
| iShares NASDAQ Biotechnology ETF | 0.65% | 825,614 | 12.17M | Feb 27, 2023 |
| Franklin Strategic Series-Franklin Biotechnology Discove | 0.46% | 587,700 | 8.66M | Jan 30, 2023 |
| Lord Abbett Securities Trust-Micro-Cap Growth Fund | 0.22% | 282,972 | 4.17M | Jan 30, 2023 |
| John Hancock Global Thematic Opportunities Fd | 0.14% | 178,544 | 2.63M | Feb 27, 2023 |
| EQ Advisors Trust-1290 VT Micro Cap Port | 0.12% | 150,030 | 2.21M | Dec 30, 2022 |